Payment overview · 2025
General Payments
$86.32
5 reported records · 1 companies
Healthcare provider profile · identity verified
Gregory Lee Stamper, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WILLISTON, FL · NPI 1790765592
Verified facts
What the public records show
CMS Open Payments records show Gregory Lee Stamper, DO received $86.32 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.32 | 100.0% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $86.32 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.32 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $86.32 | 5 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 581 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 155 |
| Lisinopril | Lisinopril | 417 | 120 |
| Losartan Potassium | Losartan Potassium | 381 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 99 |
| Oxycodone Hcl | Oxycodone Hcl | 327 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 74 |
| Gabapentin | Gabapentin | 255 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 254 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 68 |
| Alprazolam | Alprazolam | 221 | 37 |
| Omeprazole | Omeprazole | 208 | 58 |
| Trazodone Hcl | Trazodone Hcl | 200 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 52 |
| Tramadol Hcl | Tramadol Hcl | 190 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 47 |
| Furosemide | Furosemide | 166 | 51 |
| Metformin Hcl Er | Metformin Hcl | 160 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 20 |
| Eliquis | Apixaban | 149 | 29 |
| Simvastatin | Simvastatin | 145 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 45 |
| Montelukast Sodium | Montelukast Sodium | 126 | 32 |
| Metformin Hcl | Metformin Hcl | 121 | 35 |
| Sertraline Hcl | Sertraline Hcl | 121 | 32 |
| Carvedilol | Carvedilol | 120 | 37 |
| Potassium Chloride | Potassium Chloride | 115 | 33 |
| Allopurinol | Allopurinol | 113 | 33 |
| Clonazepam | Clonazepam | 110 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 22 |
| Jardiance | Empagliflozin | 97 | 24 |
| Prednisone | Prednisone | 96 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 24 |
| Famotidine | Famotidine | 83 | 22 |
| Glipizide | Glipizide | 81 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 28 |
| Glipizide Er | Glipizide | 80 | 22 |
| Meloxicam | Meloxicam | 77 | 22 |
| Januvia | Sitagliptin Phosphate | 74 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 21 |
| Atenolol | Atenolol | 71 | 19 |
| Amoxicillin | Amoxicillin | 66 | 49 |
| Cephalexin | Cephalexin | 66 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 21 |
| Lorazepam | Lorazepam | 63 | 18 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 16 |
| Rybelsus | Semaglutide | 59 | 12 |
| Celecoxib | Celecoxib | 58 | 20 |
| Ibuprofen | Ibuprofen | 56 | 19 |
| Warfarin Sodium | Warfarin Sodium | 56 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 42 |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Ondansetron Odt | Ondansetron | 44 | 20 |
| Ozempic | Semaglutide | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 11 |
| Mupirocin | Mupirocin | 41 | 24 |
| Pregabalin | Pregabalin | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 17 |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 21 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 20 |
| Fluconazole | Fluconazole | 28 | 17 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Naproxen | Naproxen | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Baclofen | Baclofen | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Nystatin | Nystatin | 19 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $86.32 · 5 records | PFIZER INC. | ELIQUIS, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error